Skip to main content
. 2024 Jan 26;5(2):101394. doi: 10.1016/j.xcrm.2024.101394

Figure 4.

Figure 4

The evolutionary landscape of the tumor and the TME

(A‒K) The composition of tumor cells and the TME during tumor evolution for patients H73 (A), H85 (B), H77 (C), H68 (D), C26 (E), C46 (F), H08 (G), H58 (H), H01 (I), H49 (J), and H34 (K). Levels of alpha-fetoprotein (AFP) or cancer antigen 19-9 (CA 19-9) are indicated for HCC and iCCA patients, respectively. Not every sample has both detectable malignant and non-malignant single cells. The baseline sample for patient C46 only has five malignant cells and is excluded from our analyses but is shown here for reference.